• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CKS2(CDC28 蛋白激酶调节亚基 2)是低级别胶质瘤的预后生物标志物:基于生物信息学分析和免疫组织化学的研究。

CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.

机构信息

Department of Pathology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.

出版信息

Bioengineered. 2021 Dec;12(1):5996-6009. doi: 10.1080/21655979.2021.1972197.

DOI:10.1080/21655979.2021.1972197
PMID:34494924
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8806895/
Abstract

Gliomas account for the highest cases of primary brain malignancies. Whereas previous studies have demonstrated the roles of CDC28 Protein Kinase Regulatory Subunit 2 (CKS2) in various cancer types, its functions in lower grade gliomas (LGGs) remain elusive. This study aimed to profile the expression and functions of CKS2 in LGG. Multiple online databases such as The Cancer Genome Atlas (TCGA), the Chinese Glioma Genome Atlas (CGGA), Gene Expression Profiling Interactive Analysis 2nd edition (GEPIA2), Tumor Immune Estimation Resource 2nd edition (TIMER2.0) as well as Gene Expression Omnibus (GEO) were used in this study. Immunohistochemistry (IHC) was performed to evaluate CKS2 protein expression. Our data demonstrated upregulation of CKS2 in LGG tissues at both mRNA and protein level, especially in grade III gliomas. Similarly, there was increased expression of CKS2 in isocitrate dehydrogenase 1 (IDH1) wildtype gliomas. In addition, increased DNA copy number and DNA hypomethylation might be associated with the upregulation of the CKS2 in LGG. Using the Kaplan-Meier survival analysis and the Cox regression analysis, CKS2 was shown to be independently associated with poor prognosis of LGG patients. Receiver operating characteristic (ROC) analysis revealed that CKS2 could effectively predict the 1-, 3- and 5-year survival rates of LGG patients. Enrichment analyses revealed that CKS2 was mainly involved in the regulation of the cell cycle in LGG. Taken together, our study demonstrated that CKS2 might be a candidate prognostic biomarker for LGG and could predict the survival rates of LGG patients. LGG: lower grade glioma; CKS2: CDC28 protein kinase regulatory subunit 2; TCGA: The Cancer Genome Atlas; CGGA: the Chinese Glioma Genome Atlas; GEO: Gene Expression Omnibus; GEPIA: Gene Expression Profiling Interactive Analysis; TIMER: Tumor Immune Estimation Resource; IHC: immunohistochemistry; qRT-PCR: quantitative real-time polymerase chain reaction; PBS: phosphate buffered saline; DAB: diaminobenzidine tetrachloride; OS: overall survival; CAN: copy number alteration; IDH: Isocitrate dehydrogenase; GSEA: Gene Set Enrichment Analysis; DEG: differentially expressed gene; KEGG: Kyoto encyclopedia of genes and genomes; GO: Gene ontology; BP: biological process; CC: cellular component; MF: molecular function; NES: normalized enrichment score; NOM: nominal; FDR: false discovery rate.

摘要

神经胶质瘤占原发性脑恶性肿瘤的最高比例。虽然先前的研究已经证明了 CDC28 蛋白激酶调节亚基 2(CKS2)在各种癌症类型中的作用,但它在低级别神经胶质瘤(LGG)中的功能仍不清楚。本研究旨在描绘 CKS2 在 LGG 中的表达和功能。本研究使用了多个在线数据库,如癌症基因组图谱(TCGA)、中国神经胶质瘤基因组图谱(CGGA)、基因表达谱交互式分析第 2 版(GEPIA2)、肿瘤免疫估计资源第 2 版(TIMER2.0)和基因表达综合数据库(GEO)。免疫组织化学(IHC)用于评估 CKS2 蛋白表达。我们的数据表明,CKS2 在 LGG 组织中的 mRNA 和蛋白质水平均上调,特别是在 3 级神经胶质瘤中。同样,在异柠檬酸脱氢酶 1(IDH1)野生型神经胶质瘤中也有 CKS2 的表达增加。此外,DNA 拷贝数增加和 DNA 低甲基化可能与 LGG 中 CKS2 的上调有关。通过 Kaplan-Meier 生存分析和 Cox 回归分析,表明 CKS2 与 LGG 患者的不良预后独立相关。接受者操作特征(ROC)分析表明,CKS2 可有效预测 LGG 患者的 1 年、3 年和 5 年生存率。富集分析表明,CKS2 主要参与 LGG 中细胞周期的调节。总之,我们的研究表明 CKS2 可能是 LGG 的候选预后生物标志物,并可预测 LGG 患者的生存率。LGG:低级别神经胶质瘤;CKS2:CDC28 蛋白激酶调节亚基 2;TCGA:癌症基因组图谱;CGGA:中国神经胶质瘤基因组图谱;GEO:基因表达综合数据库;GEPIA:基因表达谱交互式分析;TIMER:肿瘤免疫估计资源;IHC:免疫组织化学;qRT-PCR:实时定量聚合酶链反应;PBS:磷酸盐缓冲盐水;DAB:二氨基联苯四氯;OS:总生存期;CAN:拷贝数改变;IDH:异柠檬酸脱氢酶;GSEA:基因集富集分析;DEG:差异表达基因;KEGG:京都基因与基因组百科全书;GO:基因本体论;BP:生物学过程;CC:细胞成分;MF:分子功能;NES:标准化富集分数;NOM:名义;FDR:错误发现率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1dc9/8806895/2e1deff434c0/KBIE_A_1972197_F0008_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1dc9/8806895/9f9f76814140/KBIE_A_1972197_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1dc9/8806895/9397e69153c9/KBIE_A_1972197_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1dc9/8806895/b8b6f49f68ea/KBIE_A_1972197_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1dc9/8806895/3d05a7792dd9/KBIE_A_1972197_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1dc9/8806895/e9233fb89569/KBIE_A_1972197_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1dc9/8806895/5a4352887145/KBIE_A_1972197_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1dc9/8806895/5f9e8f1715b2/KBIE_A_1972197_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1dc9/8806895/2e1deff434c0/KBIE_A_1972197_F0008_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1dc9/8806895/9f9f76814140/KBIE_A_1972197_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1dc9/8806895/9397e69153c9/KBIE_A_1972197_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1dc9/8806895/b8b6f49f68ea/KBIE_A_1972197_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1dc9/8806895/3d05a7792dd9/KBIE_A_1972197_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1dc9/8806895/e9233fb89569/KBIE_A_1972197_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1dc9/8806895/5a4352887145/KBIE_A_1972197_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1dc9/8806895/5f9e8f1715b2/KBIE_A_1972197_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1dc9/8806895/2e1deff434c0/KBIE_A_1972197_F0008_OC.jpg

相似文献

1
CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.CKS2(CDC28 蛋白激酶调节亚基 2)是低级别胶质瘤的预后生物标志物:基于生物信息学分析和免疫组织化学的研究。
Bioengineered. 2021 Dec;12(1):5996-6009. doi: 10.1080/21655979.2021.1972197.
2
High Expression of CKS2 Predicts Adverse Outcomes: A Potential Therapeutic Target for Glioma.CKS2 高表达预示不良结局:胶质瘤潜在的治疗靶点。
Front Immunol. 2022 May 19;13:881453. doi: 10.3389/fimmu.2022.881453. eCollection 2022.
3
Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.丝氨酸掺入因子 2(SERINC2)表达预测低级别胶质瘤(LGG)的不良预后:来自生物信息学分析的证据。
J Mol Neurosci. 2020 Oct;70(10):1521-1532. doi: 10.1007/s12031-020-01620-w. Epub 2020 Jul 8.
4
SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.SYT16 是胶质母细胞瘤的预后生物标志物,并与免疫浸润相关:基于 TCGA 数据的研究。
Int Immunopharmacol. 2020 Jul;84:106490. doi: 10.1016/j.intimp.2020.106490. Epub 2020 Apr 11.
5
Phospholipase Cγ1 (PLCG1) overexpression is associated with tumor growth and poor survival in IDH wild-type lower-grade gliomas in adult patients.磷脂酶 Cγ1(PLCG1)过表达与 IDH 野生型成人低级别胶质瘤的肿瘤生长和不良预后相关。
Lab Invest. 2022 Feb;102(2):143-153. doi: 10.1038/s41374-021-00682-7. Epub 2021 Oct 25.
6
EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.EFNA1 是与低级别胶质瘤免疫浸润相关的潜在关键基因。
Medicine (Baltimore). 2021 Jun 4;100(22):e26188. doi: 10.1097/MD.0000000000026188.
7
SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.SHOX2是预测世界卫生组织II-III级弥漫性胶质瘤患者生存的有效独立生物标志物。
EBioMedicine. 2016 Nov;13:80-89. doi: 10.1016/j.ebiom.2016.10.040. Epub 2016 Oct 28.
8
Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.TYROBP 表达升高预示低级别胶质瘤患者预后不良和肿瘤免疫浸润程度高。
BMC Cancer. 2021 Jun 23;21(1):723. doi: 10.1186/s12885-021-08456-6.
9
Identification of Hub Gene GRIN1 Correlated with Histological Grade and Prognosis of Glioma by Weighted Gene Coexpression Network Analysis.基于加权基因共表达网络分析鉴定与胶质瘤组织学分级和预后相关的枢纽基因 GRIN1。
Biomed Res Int. 2021 Nov 19;2021:4542995. doi: 10.1155/2021/4542995. eCollection 2021.
10
An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.预测低级别胶质瘤预后的免疫相关标志物。
Front Immunol. 2020 Dec 8;11:603341. doi: 10.3389/fimmu.2020.603341. eCollection 2020.

引用本文的文献

1
Biological functions and therapeutic potential of CKS2 in human cancer.CKS2在人类癌症中的生物学功能及治疗潜力
Front Oncol. 2024 Aug 12;14:1424569. doi: 10.3389/fonc.2024.1424569. eCollection 2024.
2
Global trends and hotspots in Cyclin-dependent Kinase Subunit 2 research from 1999 to 2022: A bibliometric and visualized analysis.1999 年至 2022 年细胞周期蛋白依赖性激酶亚单位 2 研究的全球趋势和热点:文献计量学和可视化分析。
Medicine (Baltimore). 2023 Dec 1;102(48):e36319. doi: 10.1097/MD.0000000000036319.
3
Short-hairpin RNA-mediated suppression of cortactin may inhibit the migration and invasion abilities of endometrial cancer cells by reducing lamellipodia.

本文引用的文献

1
Age-Associated Proteomic Signatures and Potential Clinically Actionable Targets of Colorectal Cancer.与年龄相关的结直肠癌蛋白质组学特征及潜在的临床可操作靶点。
Mol Cell Proteomics. 2021;20:100115. doi: 10.1016/j.mcpro.2021.100115. Epub 2021 Jun 12.
2
A Novel Four-Gene Signature Associated With Immune Checkpoint for Predicting Prognosis in Lower-Grade Glioma.一种与免疫检查点相关的新型四基因特征用于预测低级别胶质瘤的预后
Front Oncol. 2020 Oct 30;10:605737. doi: 10.3389/fonc.2020.605737. eCollection 2020.
3
Analysis of Collagen type X alpha 1 (COL10A1) expression and prognostic significance in gastric cancer based on bioinformatics.
短发夹RNA介导的皮层肌动蛋白抑制可能通过减少片状伪足来抑制子宫内膜癌细胞的迁移和侵袭能力。
Iran J Basic Med Sci. 2023;26(12):1390-1399. doi: 10.22038/IJBMS.2023.67633.14863.
4
Identification of as a novel prognostic biomarker and potential therapeutic target for oral squamous cell carcinoma.鉴定某物质作为口腔鳞状细胞癌的一种新型预后生物标志物和潜在治疗靶点。 (你原文中“Identification of ”后面缺少具体内容,我按正常补充了“某物质”来翻译完整句子意思)
Transl Cancer Res. 2023 Sep 30;12(9):2276-2293. doi: 10.21037/tcr-23-511. Epub 2023 Sep 12.
5
Expression of CKS2 in Hepatocellular Carcinoma: Correlation with Survival Outcomes and Immune Microenvironment.CKS2在肝细胞癌中的表达:与生存结果及免疫微环境的相关性
J Hepatocell Carcinoma. 2023 Oct 9;10:1767-1784. doi: 10.2147/JHC.S427624. eCollection 2023.
6
PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma.PLEKHA4 是一种新型的预后生物标志物,可重塑低级别脑胶质瘤的肿瘤微环境。
Front Immunol. 2023 Sep 25;14:1128244. doi: 10.3389/fimmu.2023.1128244. eCollection 2023.
7
Identifying the shared genes and KEGG pathways of Resolvin D1-targeted network and osteoarthritis using bioinformatics.利用生物信息学鉴定 Resolvin D1 靶向网络与骨关节炎的共有基因和 KEGG 通路。
Bioengineered. 2022 Apr;13(4):9839-9854. doi: 10.1080/21655979.2022.2061288.
基于生物信息学的胃癌中胶原类型 X 阿尔法 1(COL10A1)表达分析及其预后意义。
Bioengineered. 2021 Dec;12(1):127-137. doi: 10.1080/21655979.2020.1864912.
4
Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas.组织病理学分级影响 IDH 突变型 II 级和 III 级弥漫性神经胶质瘤患者的生存。
Eur J Cancer. 2020 Sep;137:10-17. doi: 10.1016/j.ejca.2020.06.018. Epub 2020 Jul 26.
5
TIMER2.0 for analysis of tumor-infiltrating immune cells.TIMER2.0 用于分析肿瘤浸润免疫细胞。
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514. doi: 10.1093/nar/gkaa407.
6
ZW10 interacting kinetochore protein may serve as a prognostic biomarker for human breast cancer: An integrated bioinformatics analysis.ZW10相互作用的动粒蛋白可能作为人类乳腺癌的预后生物标志物:一项综合生物信息学分析。
Oncol Lett. 2020 Mar;19(3):2163-2174. doi: 10.3892/ol.2020.11353. Epub 2020 Jan 24.
7
Cyclin-Dependent Kinase Regulatory Subunit 2 Indicated Poor Prognosis and Facilitated Aggressive Phenotype of Hepatocellular Carcinoma.细胞周期蛋白依赖性激酶调节亚基 2 预示着肝癌不良预后并促进其侵袭性表型。
Dis Markers. 2019 Oct 22;2019:8964015. doi: 10.1155/2019/8964015. eCollection 2019.
8
GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis.GEPIA2:一个用于大规模表达谱分析和交互式分析的增强型网络服务器。
Nucleic Acids Res. 2019 Jul 2;47(W1):W556-W560. doi: 10.1093/nar/gkz430.
9
The antibiotic clofoctol suppresses glioma stem cell proliferation by activating KLF13.抗生素氯氟醇通过激活 KLF13 抑制神经胶质瘤干细胞增殖。
J Clin Invest. 2019 May 21;129(8):3072-3085. doi: 10.1172/JCI124979.
10
CKS2 promotes tumor progression and metastasis and is an independent predictor of poor prognosis in epithelial ovarian cancer.CKS2 促进肿瘤进展和转移,是上皮性卵巢癌不良预后的独立预测因子。
Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3225-3234. doi: 10.26355/eurrev_201904_17681.